Department of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Lasers Surg Med. 2021 Oct;53(8):1065-1072. doi: 10.1002/lsm.23393. Epub 2021 Feb 19.
The long-term efficacy of a picosecond alexandrite laser (PSAL) with a diffractive lens array (DLA) for the treatment of photoaging is absent. To observe the long-term efficacy of PSAL for the treatment of photoaging.
STUDY DESIGN/MATERIALS AND METHODS: Each patient (n = 10) received 10 treatments at 2-week intervals. One side of the face was randomly selected for treatment. At 1, 3, 6, and 36 months after the final treatment, two blinded physicians evaluated photographs with four clinical indicators of photoaging (dyschromia, skin texture, skin laxity, and rhytids). A quartile scale was used.
At baseline, there were no significant differences in dyschromia, skin texture, facial laxity, or rhytids between the treated and control sides (P > 0.05). Picosecond laser-treated side showed 0.85 and 1.05 (both P < 0.05) better for dyschromia at 3- and 6-month follow-up, and 0.6 (P < 0.05) better for skin texture at 6-month follow-up. At 36-month follow-up, the degree of photoaging is intensified on the control side while the rejuvenation efficacy maintained on the treated side, with 1.4, 0.75, and 0.8 (all P < 0.05) better for dyschromia, skin texture, and rhytids relative to the control side measures.
Our results demonstrate the long-term efficacy and safety of PSAL with DLA for the treatment of facial photoaging.
Small sample size and the lack of objective evaluation. Lasers Surg. Med. © 2021 Wiley Periodicals LLC.
目前尚无长脉冲倍频翠绿宝石激光(PSAL)联合衍射透镜阵列(DLA)治疗光老化的长期疗效报道。本研究旨在观察 PSAL 治疗光老化的长期疗效。
研究设计/材料和方法:每位患者(n=10)接受 10 次 2 周间隔的治疗。随机选择一侧面部进行治疗。在末次治疗后 1、3、6 和 36 个月,两名盲法医生使用 4 项光老化临床指标(色素异常、皮肤质地、皮肤松弛和皱纹)评估照片。采用四分位尺度进行评估。
治疗前,治疗侧和对照侧的色素异常、皮肤质地、面部松弛和皱纹无显著差异(P>0.05)。在 3 个月和 6 个月随访时,PSAL 治疗侧色素异常分别改善了 0.85 和 1.05 分(均 P<0.05),在 6 个月随访时皮肤质地改善了 0.6 分(P<0.05)。在 36 个月随访时,对照侧的光老化程度加重,而治疗侧的年轻化效果保持,治疗侧色素异常、皮肤质地和皱纹分别改善了 1.4、0.75 和 0.8 分(均 P<0.05)。
我们的结果表明 PSAL 联合 DLA 治疗面部光老化具有长期疗效和安全性。
样本量小且缺乏客观评价。《激光医学杂志》。© 2021 年 Wiley 期刊有限公司。